| Active ingredient (INN) |
|---|
| Dabrafenib |
| Brand names | Tafinlar |
|---|
| ATC level 5 | L01EC02 |
|---|
| ATC level 4 | L01EC |
|---|
| Therapeutic category | Auto-created by National Organisation for Medicines — Drug Shortages scraper |
|---|
| Controlled substance | No |
|---|
| Marketing-authorisation holders | Novartis Pharmaceuticals Australia Pty Ltd |
|---|
| Registrations on file | 3 |
|---|
| Patient information leaflet (PIL) | Not on file |
|---|
| Summary of product characteristics (SPC) | Not on file |
|---|
| Product | Strength | Form | Market | MA holder | Status |
|---|---|---|---|---|---|
| TAFINLAR dabrafenib | 10 mg | — | 🇦🇺 AU | Novartis Pharmaceuticals Australia Pty Ltd | Active |
| TAFINLAR dabrafenib | 75 mg | — | 🇦🇺 AU | Novartis Pharmaceuticals Australia Pty Ltd | Active |
| TAFINLAR dabrafenib | 50 mg | — | 🇦🇺 AU | Novartis Pharmaceuticals Australia Pty Ltd | Active |